Clinical Trial Update: Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the antidepressant effects of AV-101 (4-chlorokynurenine), a glycine receptor antagonist, in major depressive disorder has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AV-101

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Major Depression | Phase 2 | Status: COMPLETED | Results posted: 2022-03-02